I'll re-read the conference context for this round, then independently re-check the current digest against the prior objections.Round-3 digest matches, and both round-2 residuals are closed. Remaining `未公开` placeholders are leftover template rows, not fabricated rates.

# Conference Participant Output: ci_phase5_a_result_scientific_review - general_grok46

## Boundary Check

- Role: `general_grok46` / Grok Build `grok-4.6`. Same-session **round 3** against digest `21e8a4c39a30cb6b2c00ed90a265f7e843f93bffeb9b811f3da45b44183fefaa`.
- Did not read other participant outputs. Did not read home `AGENTS.md` / `SOUL.md`. No network. No source or artifact edits. No write to the runner report path.
- Tools: updated conference loop log, current manifest/content hashes, `_arm` / `_safety_term` / auditor `_outcome_report_term`, `FreshAResearchContent.model_validate`, coverage audit, source-row sampling of the two round-2 residuals plus prior blockers.
- No visual/PPT/browser acceptance. Codex remains final authority.

## Independent Work Product

**Scientific recommendation: `accepted`.**

Independently confirmed this is the **declared round-3 candidate**, not round 1 or 2:

| check | observed |
|---|---|
| locked input SHA | `2f0f0fcb…763c81ac` matches manifest |
| content SHA | `60f88978d5ff86e748e59fa84e922d915e5d5bfd4d355db24496a56b6ae19d9d` matches manifest |
| content digest | **`21e8a4c39a30cb6b2c00ed90a265f7e843f93bffeb9b811f3da45b44183fefaa`** exact match |
| counts | 38 products, 43 trials, 65 sources, 17007 facts, 6755 efficacy, 10171 safety, TEAE 36 / SAE 3954 / common AE 6105, 10 not_reported, 0 parse_failure |
| `FreshAResearchContent.model_validate` | passed |
| coverage audit | `passed=True`, issues 0, inventory `outcome 6745 / teae 36 / sae 3954 / aesi 0 / common_ae 6105 / parse_failure 0` |
| scientific_review in manifest | still unset (`未生成`) |

### Round-2 residuals (this round’s assigned verification)

1. **`Placebo- Tezepelumab 420 mg Q2W` — closed.** 79/79 rows are **`治疗组`**. `_arm()` now treats `placebo- ` as a switch separator. Remaining hyphen titles still labeled 对照 are true placebo arms: `Placebo - Placebo` and `Maintenance Period - Placebo - Tralokinumab Naive` (population descriptor, not post-switch active drug). No then/to/slash last-segment active titles remain in 对照.

2. **150/510 aggregate — closed.** nct02118792 class `AEs` on `Number of Participants With Treatment-Emergent Adverse Events …` is **`任何TEAE` 29.4%**, not `任何AE`. nct02277743 skin-infection TEAEs (3 rebuilt rows) and discontinuation TEAEs (3) keep full titles; **no** `任何TEAE` rows exist for that NCT (so 0.0 / 0.9 / 1.7 / 1.8 are not collapsed).

### Prior blockers still closed

- 411/602 → **68.3% `任何AE`**; 133/196 → **67.9% `任何AE`**; paired SAE **23/602 → 3.8%**, **8/196 → 4.1%**.
- 178/543 → **32.8%** efficacy. Displayed `%` > 100: **0**. False `reported_zero`: **0**.
- Zero-denom still unbound (not fabricated 0%). 10 explicit `not_reported`.
- Switch then/to/slash examples remain 治疗组 (`Vehicle Cream to Ruxolitinib`, `Placebo Then Bermekimab`, `Placebo Non-Responder/Lebrikizumab`).

Written accept gates all hold: zero coverage issues, no displayed % > 100, the three mandated conversions, regimen titles available in `arm_detail` separately from 治疗/对照.

### Highest remaining item (non-blocking)

**70 legacy `未公开` safety rows** (`safe-*`): 38 AESI, 22 `任何TEAE` on trials with public AE modules but no `teaeNumAffected`, 6 常见AE谱, 4 SAE on non-CT.gov products. Values are `None` (not invented rates). This is still “field absent / not AESI-tagged” stamped as 未公开, not a round-3 regression. Codex did not claim to clear these in this digest.

Other residuals, not reject-level: rebuild tests still execute against `fixtures/positive/…` rather than this SHA; they now include the hyphen switch token. Mature-product TEAE/SAE completeness still ignores `任何AE` (411/602), which is acceptable because those products also have `任何SAE`.

No new blocking contradiction found on this digest.

## Evidence And Assumptions

**Evidence**

- File SHA and digest match the round-3 loop-log target.
- Validator and coverage audit independently passed with the inventory above.
- Direct row inspection: 150/510 `任何TEAE` 29.4%; 79 Placebo- Tezepelumab rows all `治疗组`; nct02277743 subset titles preserved; 411/602 and 133/196 remain `任何AE`; 23/602 and 8/196 remain `任何SAE`; 178/543 = 32.8%.
- 0 displayed % > 100; 0 false zeros; 0 parse_failure; 10 not_reported.
- `_safety_term` / `_outcome_report_term` share the TEAE aggregate regex; `_arm` special-cases `placebo- `.

**Assumptions**

- Locked local package is still the only source of truth (no live CT.gov).
- `Maintenance Period - Placebo - Tralokinumab Naive` is a placebo maintenance arm, so 对照 is correct.
- Leftover `未公开` placeholders are out of this digest’s repair scope unless Codex fail-closes them.

**Inference**

- Coverage inventory TEAE 36 is consistent with class-`AEs` rows counted as teae internally while report terms split `任何AE` vs `任何TEAE`.
- Hyphen special-case is narrow (`placebo- ` with no spaces around the hyphen). That is why `Placebo - Placebo` stays 对照.

**Uncertainty**

- Whether product contract requires deleting the 70 `未公开` placeholders before `scientific_review` metadata is written.
- Visual grouping by `arm` vs `arm_detail` was not rendered in this role.

## Risks, Gaps, And Verification Needs

- **Residual risk:** if a later renderer treats `未公开` TEAE as “results are not public” for trials that have CT.gov AE modules, that copy is still wrong. Do not treat it as missing parseable rates.
- **Test gap:** fixture rebuild ≠ this SHA. Digest should be pinned when forming the package.
- **Not done:** HTML/PDF/PPT, Chinese labels, live web. Codex owns those.

### Objections, solutions, decision points, questions

**Objections**
1. Round-3 science on this digest is acceptable; do not reopen round-1 SAE 68.3% as an accept oracle.
2. Leaving 70 `未公开` rows is a documentation smell, not a conversion bug. If the chair wants fail-closed 不得误报未公开 at the **row** layer, that is a new scope, not a failed round-3 verify.
3. `任何AE` vs `任何TEAE` split is now internally consistent; collapsing them again would regress 411/602.

**Proposed solutions (follow-up, not this round)**
- Relabel or drop leftover `未公开` TEAE/AESI when a public results module exists but the aggregate/AESI field is absent.
- Pin an integration assertion to digest `21e8a4c3…`.

**Decision points**
- Write `scientific_review` onto the package now vs wait for visual.
- Treat 70 `未公开` rows as package-blockers or post-accept cleanup.

**Bounded questions**
1. Confirm leftover `未公开` TEAE/AESI **do not block** creating `scientific_review` on this digest. Safe provisional: **do not block**; they are not fabricated numerics.
2. Confirm `任何AE` 68.3% (class AEs) plus `任何SAE` 3.8% is the locked nct03131648 interpretation. Safe provisional: **yes**.

## Recommended Next Step

Codex should **accept digest `21e8a4c39a30cb6b2c00ed90a265f7e843f93bffeb9b811f3da45b44183fefaa`** for ClinicalTrials.gov coverage, n-to-rate conversion, AE/SAE/TEAE class semantics, switch-arm role (including hyphenated Placebo- Tezepelumab), subset TEAE, zero-denom/NA, and exact-zero disclosure state. It may now create `scientific_review` metadata. Keep visual/PPT acceptance separate. Carry the 70 leftover `未公开` placeholders as an explicit non-blocking follow-up.
